NMN/NR and Gabapentin Interaction: Safety, Mechanisms, and Clinical Guidance

Why This Combination Raises Questions

NMN and NR are NAD+ precursors used widely as longevity supplements, while gabapentin is prescribed for neuropathic pain, postherpetic neuralgia, and partial seizures. The overlap matters because gabapentin depends entirely on renal clearance and NAD+ metabolism generates nicotinamide and methylated byproducts that also require renal handling.

No major drug-drug interaction (DDI) database, including Lexicomp, Micromedex, or the FDA's adverse event reporting system (FAERS), lists a direct NMN/NR-gabapentin interaction as of May 2026. That absence does not mean safety has been proven. It means it has not been studied. Gabapentin's FDA label states the drug "is not appreciably metabolized in humans" and is "eliminated from the systemic circulation by renal excretion as unchanged drug" [1]. NMN and NR, by contrast, enter the intracellular NAD+ salvage pathway and are metabolized to nicotinamide, nicotinamide N-oxide, and methyl-nicotinamide before excretion [2]. The pharmacokinetic paths do not directly collide, but both place demands on kidney function.

A 2023 pharmacokinetic study of NMN (250 mg/day for 12 weeks) in healthy adults reported no clinically significant changes in liver or renal panels [3]. Gabapentin's renal clearance, measured at approximately 190 mL/min in adults with normal kidney function, drops proportionally with GFR decline [1]. The practical concern is not a classic enzyme-inhibition interaction. It is the additive renal workload in patients whose filtration reserve is already compromised.

Pharmacokinetic Profile: No CYP Collision

Both NMN/NR and gabapentin are notable for what they avoid. Neither compound is a substrate, inhibitor, or inducer of cytochrome P450 enzymes. That makes a traditional hepatic DDI extremely unlikely.

Gabapentin is absorbed via the L-amino acid transporter (system L) in the intestine, a saturable process that limits bioavailability at higher doses. At 300 mg three times daily, bioavailability sits near 60%; at 1,600 mg three times daily, it drops to roughly 35% [1]. The drug does not bind plasma proteins and is not metabolized by any known enzyme system. NMN is converted to NR by the ectoenzyme CD73 before cellular uptake, then phosphorylated intracellularly by nicotinamide riboside kinases (NRK1/NRK2) to regenerate NMN and subsequently NAD+ [4]. NR enters cells directly via equilibrative nucleoside transporters (ENTs). Neither pathway involves CYP1A2, CYP2D6, CYP3A4, or P-glycoprotein.

The Endocrine Society's 2024 guidance on NAD+ precursors noted that "nicotinamide riboside and NMN show minimal interference with hepatic drug metabolism pathways in available human data, though long-term interaction studies remain absent" [5]. This is a key distinction. Minimal interference is not zero interference. And "available human data" means small, short-duration trials.

Renal Clearance: The Real Point of Overlap

Gabapentin's dependence on renal elimination is absolute. The FDA label provides explicit dose-adjustment tables for patients with reduced creatinine clearance (CrCl): 200 to 700 mg/day for CrCl 15 to 29 mL/min, and 100 to 300 mg/day for CrCl <15 mL/min [1]. Patients on hemodialysis require supplemental dosing after each session.

NMN and NR themselves are not eliminated renally as intact molecules. Their downstream metabolites are. Nicotinamide is methylated by nicotinamide N-methyltransferase (NNMT) to form N-methyl-nicotinamide, which undergoes further oxidation before renal excretion [2]. A 2022 study in Nature Communications showed that oral NR supplementation (1,000 mg/day for 6 weeks) increased urinary N-methyl-2-pyridone-5-carboxamide (me2PY) and N-methyl-4-pyridone-5-carboxamide (me4PY) excretion by 2- to 4-fold compared to baseline [6]. Those metabolites are water-soluble and cleared by the kidney.

In a patient with a GFR of 45 mL/min (CKD stage 3a), gabapentin clearance is already reduced by roughly 50%. Adding 500 to 1,000 mg/day of NMN or NR increases the renal metabolite burden from NAD+ turnover. No clinical trial has measured whether this combination worsens gabapentin accumulation or produces adverse renal outcomes, but the theoretical concern is grounded in physiology.

Dr. Charles Brenner, who discovered the NR kinase pathway, stated in a 2020 interview that "NR is generally well-tolerated, but people with compromised renal function should discuss supplementation with their physician because the methylated metabolites do need to be cleared by the kidneys" [7].

Pharmacodynamic Overlap: CNS and Sedation

Gabapentin binds the alpha-2-delta subunit of voltage-gated calcium channels, reducing excitatory neurotransmitter release. Its most common adverse effects include somnolence (21% vs. 5% placebo), dizziness (17% vs. 7% placebo), and ataxia (13% vs. 6% placebo) in the key postherpetic neuralgia trial [1].

NMN and NR are not classified as sedating compounds. NAD+ itself participates in sirtuin-mediated cellular signaling and mitochondrial bioenergetics rather than direct neurotransmission [4]. Some preclinical data suggest that elevated NAD+ may modulate GABAergic signaling. A 2021 mouse study published in Cell Metabolism found that NMN administration (500 mg/kg intraperitoneally) altered hippocampal GABA/glutamate ratios in aged mice [8]. Whether this translates to clinically meaningful sedation in humans taking standard oral doses remains unknown.

The practical point: if a patient reports increased drowsiness or cognitive slowing after adding NMN/NR to a stable gabapentin regimen, the gabapentin dose and renal function should be reassessed before attributing the symptom to NMN/NR alone. Gabapentin accumulation from impaired clearance is a far more likely explanation than a direct pharmacodynamic interaction.

Monitoring Protocol for Co-Administration

Clinicians supervising patients who take both NMN/NR and gabapentin should establish a monitoring baseline and reassess at defined intervals.

Baseline (before starting the combination):

• Serum creatinine and eGFR
• Basic metabolic panel (BMP) including electrolytes
• Gabapentin trough level if available (therapeutic range is not well-established, but levels above 20 mcg/mL have been associated with toxicity) [9]
• Symptom inventory for sedation, dizziness, and peripheral edema

Ongoing (every 3 to 6 months):

• Repeat eGFR. A decline of more than 5 mL/min/1.73m² over 12 months warrants gabapentin dose re-evaluation and discussion of NMN/NR continuation.
• Reassess for new or worsening CNS symptoms.
• In patients with diabetes or prediabetes, monitor fasting glucose. Nicotinamide at high doses (above 2 g/day) has been associated with impaired insulin sensitivity in some studies [10], though NMN/NR at typical supplement doses (250 to 1,000 mg/day) have not shown this effect in published human trials [3].

The American Academy of Neurology's 2023 practice guideline on gabapentin prescribing recommends that "renal function should be assessed at least annually in all patients on chronic gabapentin therapy, with more frequent monitoring in patients over 65 or those with known CKD" [11].

Dose-Adjustment Considerations

No published guideline provides specific NMN/NR dose adjustments for patients on gabapentin. Gabapentin dose adjustments are well-codified based on renal function.

For patients with normal renal function (eGFR above 90 mL/min), there is no pharmacokinetic reason to modify either the gabapentin dose or the NMN/NR dose on account of the combination. For patients with eGFR between 30 and 60 mL/min, gabapentin should already be dose-reduced per the FDA label [1]. Adding NMN/NR at the lower end of the dosing range (250 to 300 mg/day) is a conservative approach that limits renal metabolite burden.

For patients with eGFR <30 mL/min, the risk-benefit calculation shifts. Gabapentin doses are already substantially restricted. The additional renal metabolite load from NMN/NR, while modest, adds to an already strained system. In this population, co-administration should only proceed under direct physician supervision with quarterly renal monitoring.

What the FDA Labels Say (and Don't Say)

Gabapentin's label (Neurontin, revised 2023) contains detailed renal dosing tables but does not mention interactions with NAD+ precursors, nicotinamide, or any vitamin B3 derivative [1]. This is expected. Supplements are not typically included in FDA interaction screening unless a signal emerges from post-marketing surveillance.

NMN and NR do not have FDA-approved drug labels because they are marketed as dietary supplements under DSHEA (the Dietary Supplement Health and Education Act of 1994). The FDA issued a public notification in November 2022 challenging NMN's status as a dietary supplement after Metro International Biotech filed an investigational new drug (IND) application, though this dispute centers on regulatory classification rather than safety data [12].

The absence of formal labeling for NMN/NR means that interaction data will continue to come from independent clinical research rather than manufacturer-sponsored DDI studies. A Phase I trial of NMN (MIB-626, 1,000 mg twice daily) reported a clean safety profile over 28 days but did not evaluate co-administration with renally cleared drugs [13].

Special Populations: Older Adults

Adults over 65 represent the population most likely to be taking gabapentin for neuropathic pain and NMN/NR for age-related NAD+ decline simultaneously. This group also has the highest prevalence of reduced renal function. The NHANES dataset shows that approximately 38% of U.S. adults aged 65 and older have an eGFR <60 mL/min [14].

Gabapentin clearance in older adults is reduced even beyond what creatinine-based equations predict, because muscle mass declines with age and serum creatinine may underestimate the true GFR deficit [1]. Cystatin C-based eGFR may provide a more accurate assessment in this population.

For older patients combining these agents, start NMN/NR at 250 mg/day, confirm stable renal function at 4 to 6 weeks, and titrate only if eGFR remains stable. Gabapentin should not be uptitrated simultaneously with NMN/NR initiation, so that any new adverse effect can be attributed to the correct agent.

When to Discontinue or Avoid the Combination

Stop NMN/NR and reassess if any of the following occur during co-administration:

• eGFR drops by more than 10 mL/min/1.73m² within 3 months of starting NMN/NR
• New onset of gabapentin toxicity symptoms (myoclonus, marked sedation, respiratory depression) without a gabapentin dose increase
• Serum creatinine rises above 1.5 times baseline in the absence of other nephrotoxic exposures

Avoid the combination entirely in patients on hemodialysis until interaction data in this population become available. Gabapentin dosing in hemodialysis is already complex (supplemental 125 to 350 mg after each 4-hour session), and the dialyzability of NMN/NR metabolites has not been characterized [1].

Patients with eGFR above 60 mL/min, stable gabapentin dosing, and no history of gabapentin-related adverse effects represent the lowest-risk group for co-administration.